Future innovations in health care and prevention require research across a full spectrum of biomedical science, from basic and translational research to implementation science and comparative effectiveness research.
AAMC advocates for funding and appropriate regulation by major federal agencies and organizations supporting this research, including the National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ), and the Department of Veterans Affairs (VA).
Ensuring a sustainable research mission is essential to achieve long-term health priorities, develop new therapeutics and preventive measures, focus on patient-centered outcomes, and reduce health disparities.
|Comparative Effectiveness||Responsible Conduct of Research|
|Research with Animals||Stem Cell Research and Regenerative Medicine|
News and Updates
April 11, 2014
Rep. Anna G. Eshoo (D-Calif.) April 3 introduced the American HEALS (Helping Encourage Advancements in Lifesaving Science) Act (H.R. 4384) to expand support for medical research at the National Institutes of Health (NIH), the Centers for Disease Control (CDC), the Department of Defense Health Program (DHP), and the Department of Veterans Affairs (VA) Medical & Prosthetics Research Program.
April 11, 2014
A total of 186 representatives signed an April 4 letter organized by Reps. David McKinley (R-W.Va.), Susan Davis (D-Calif.), Andre Carson (D-Ind.), and Peter King (R-N.Y.) requesting that NIH receive “at least $32 billion” in FY 2015. A total of 57 senators signed an April 3 letter organized by Senators Bob Casey (D-Pa.) and Richard Burr (R-NC) requesting appropriators “maintain a strong commitment” to funding for NIH.
April 4, 2014
Both Democratic and Republican appropriators agreed on the need to increase funding for the National Institutes of Health (NIH) but provided no answers on where the additional funds could be found. The discussion took place at an April 2 hearing of the Senate Labor-HHS-Education Appropriations Subcommittee on the president’s FY 2015 budget request for the agency.
April 4, 2014
AAMC Chief Scientific Officer Ann Bonham, Ph.D., presented oral remarks April 1 at a hearing of the Food and Drug Administration (FDA) on broadening inclusion and representation of communities in research that becomes the basis for FDA’s regulatory and other decisions. The FDA Office of Minority Health held the day-long session specifically to receive public comments on the issues and challenges associated with the collection, analysis, and availability of demographic subgroup data, such as sex, race, ethnicity, or age, in applications for approval of FDA‐regulated medical products.
March 28, 2014
The House Labor, Health and Human Services, Education, and Related Agencies (Labor-HHS) Appropriations Subcommittee held a March 25 public witness hearing where two representatives from AAMC-member institutions were selected to testify.